Composition
Inj 2 mg/10 mg:Mitomycin 2 mg/10 mg.
Indications & Dosage
Recurrent superficial bladder tumours (bladder instillation), Bladder carcinoma: BY IV INJ: Adult: 20-40 mg/dose every 6-8 week (consult product literature). Chronic lymphatic leukaemia, chronic myelogenous leukaemia, Gastric, colorectal, lung, pancreatic, liver, cervix, endometrium, head & neck and breast cancer: BY IV INJ: Adults & Elderly: Monotherapy: 20 mg/m2 every 6-8 week. Combination therapy: 10 mg/m2 every 6-8 week.
Administration
Slow IV push or by slow (15-30 min) infusion via a freely-running dextrose or saline infusion. Consider using a central venous catheter. Further dilution to 20-40 mcg/ml in NS or Sodium Lactate. Dilute powder with SWFI or 0.9% sodium chloride to a concentration of 0.5-1 mg/ml.
Compatibility
Stable in LR.
Contraindications
Thrombocytopenia, coagulation disorder, increased bleeding tendency.
Precautions
Monitor renal and hepatic function and haematology, bone marrow depression, children.
Interactions
Other antineoplastics (since alkaloids, doxorubicin).
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Alopecia, bone marrow damage, bone-marrow suppression, hyperuricaemia, lung fibrosis, nausea, oral mucositis, renal damage, thromboembolism, tumourlysis syndrome, vomiting, extravasation, bone-marrow toxicity